Skip to content

Philip Mcguire

33 papers in the library · 2,282 citations · publishing 1991-2026

Papers

Sort Most recent Most cited

Insight into cannabis use disorder in people with psychotic disorders

BJPsych Open August 25, 2026 Edward Chesney, Millie Lloyd, Sébastien Brodeur et al.

BACKGROUND: Cannabis use is common in people with psychosis and is associated with poor outcomes. AIMS: To assess insight into cannabis use disorder, perceptions about how cannabis use influences mental health and the desire to change cannabis use among people with psychotic disorders. METHOD: Adults with a psychotic disorder and comorbid cannabis use disorder were asked about the impact of...

The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regression.

Neuroscience & Biobehavioral Reviews June 3, 2026 Isabella Goodwin, Dominic Oliver, Edward Chesney et al.

Global shifts towards the liberalisation of cannabis policies have increased the potency of cannabis products, alongside their accessibility, diversity, and the number of inexperienced cannabis consumers. There is a lack of systematic evidence on the subjective effects of cannabis' main psychoactive compound, Δ9-tetrahydrocannabinol (THC). We systematically reviewed and meta-analysed data from...

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.

Neuropsychopharmacology November 2025 Edward Chesney, Dominic Oliver, Ananya Sarma et al.

In patients with schizophrenia, cannabis use exacerbates symptoms and can lead to a relapse of psychosis. Some experimental studies in healthy volunteers suggest that pre-treatment with cannabidiol (CBD) may reduce these effects, but others do not. Here, we investigated whether pre-treatment with CBD ameliorates the acute adverse effects of cannabis in patients with schizophrenia. Participants...

Psychosis associated with cannabis withdrawal: systematic review and case series

The British Journal of Psychiatry December 3, 2024 Edward Chesney, Thomas J. Reilly, Fraser Scott et al.

Background Abrupt cessation of heavy cannabis use can cause a withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite and restlessness. Recent reports have also described people in whom cannabis withdrawal immediately preceded the acute onset of psychosis. Aims To identify cases of psychosis associated with cannabis withdrawal. Method We completed a systematic...

Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.

Addiction February 2024 Dominic Oliver, Amir Englund, Edward Chesney et al.

To test how attentional bias and explicit liking are influenced by delta-9-tetrahydrocannabinol (THC) and whether these effects are moderated by cannabidiol (CBD). Double-blind, randomised, within-subjects cross-over study. NIHR Wellcome Trust Clinical Research Facility at King's College Hospital, London, United Kingdom. Forty-six infrequent cannabis users (cannabis use <1 per week). Across...

Assessing Cannabis Use in People with Psychosis

Cannabis and Cannabinoid Research February 1, 2024 Edward Chesney, Will Lawn, Philip Mcguire

Introduction: Cannabis use is common in people with psychotic disorders and is associated with the exacerbation of symptoms, poor treatment adherence, and an increased risk of relapse. Accurate assessment of cannabis use is thus critical to the clinical management of psychosis. Discussion: Cannabis use is usually assessed with self-report questionnaires that were originally developed for...

Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

Psychological Medicine October 17, 2023 Cathy Davies, Matthijs Geert Bossong, Daniel Martins et al. 9 citations

ABSTRACT Background Hippocampal hyperperfusion has been observed in people at Clinical High Risk for Psychosis (CHR), is associated with adverse longitudinal outcomes and represents a potential treatment target for novel pharmacotherapies. Whether cannabidiol (CBD) has ameliorative effects on hippocampal blood flow (rCBF) in CHR patients remains unknown. Methods Using a double-blind,...

Influence of cannabis use on incidence of psychosis in people at clinical high risk

Psychiatry and Clinical Neurosciences April 18, 2023 Lucy Chester, Lucia Valmaggia, Matthew J. Kempton et al.

Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of...

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study

Cannabis and Cannabinoid Research December 9, 2022 Lucy Chester, Amir Englund, Edward Chesney et al. 20 citations

Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system. Delta-9-tetrahydrocannabinol (THC) binds to central cannabinoid receptors, while cannabidiol (CBD) may influence endocannabinoid function without directly acting on cannabinoid receptors. We examined the effects of THC coadministered with different doses of CBD...

Eye movements in patients in early psychosis with and without a history of cannabis use

Schizophrenia May 12, 2021 Musa Basseer Sami, Luciano Annibale, Aisling O’neill et al. 5 citations

Abstract It is unclear whether early psychosis in the context of cannabis use is different from psychosis without cannabis. We investigated this issue by examining whether abnormalities in oculomotor control differ between patients with psychosis with and without a history of cannabis use. We studied four groups: patients in the early phase of psychosis with a history of cannabis use (EPC; n =...

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis

Translational Psychiatry April 21, 2020 Musa Sami, Amanda Worker, Marco Colizzi et al.

AbstractThe associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29); Early...

Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.

Experimental and Clinical Psychopharmacology December 2018 Marco Colizzi, Philip Mcguire, Vincent Giampietro et al.

Cannabis can induce transient psychotic and anxiety symptoms and long-lasting disorders. The acute psychoactive effects of its main active ingredient, (-)-trans-Δ9-tetrahydrocannabinol (Δ9-THC), may be modulated by previous cannabis exposure. Secondary data analyses tested whether modest previous cannabis exposure modulated the acute effects of Δ9-THC on attentional salience and emotional...

Liberal Acceptance Bias, Momentary Aberrant Salience, and Psychosis: An Experimental Experience Sampling Study

Schizophrenia Bulletin August 6, 2018 Ulrich Reininghaus, Margaret Oorschot, Steffen Moritz et al. 33 citations

Cognitive models of psychosis posit that reasoning biases are an important mechanism contributing to the formation of psychotic symptoms, in part through transforming anomalous experiences of aberrant salience into frank psychotic symptoms. This study aimed to investigate the interplay of liberal acceptance (LA) bias, which is a specific type of reasoning bias, and momentary aberrant salience...

Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects ofδ-9-THC

Psychological Medicine March 5, 2018 Sagnik Bhattacharyya, Thomas T. J. Sainsbury, Paul Allen et al. 16 citations

BACKGROUND: Cannabis and its main psychoactive ingredient δ-9-tetrahydrocannibidiol (THC) can induce transient psychotic symptoms in healthy individuals and exacerbate them in those with established psychosis. However, not everyone experience these effects, suggesting that certain individuals are particularly susceptible. The neural basis of this sensitivity to the psychotomimetic effects of...

Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors.

Scientific Reports November 3, 2017 Sagnik Bhattacharyya, Alice Egerton, Euitae Kim et al.

Use of Cannabis, the most widely used illicit drug worldwide, is associated with acute anxiety, and anxiety disorders following regular use. The precise neural and receptor basis of these effects have not been tested in man. Employing a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC),...

Can we make cannabis safer?

The Lancet Psychiatry August 2017 Amir Englund, Tom P. Freeman, Robin Murray et al.

Cannabis use and related problems are on the rise globally alongside an increase in the potency of cannabis sold on both black and legal markets. Additionally, there has been a shift towards abandoning prohibition for a less punitive and more permissive legal stance on cannabis, such as decriminalisation and legalisation. It is therefore crucial that we explore new and innovative ways to reduce...

Stress Sensitivity, Aberrant Salience, and Threat Anticipation in Early Psychosis: An Experience Sampling Study

Schizophrenia Bulletin February 1, 2016 Ulrich Reininghaus, Matthew J. Kempton, Lucia Valmaggia et al. 315 citations

While contemporary models of psychosis have proposed a number of putative psychological mechanisms, how these impact on individuals to increase intensity of psychotic experiences in real life, outside the research laboratory, remains unclear. We aimed to investigate whether elevated stress sensitivity, experiences of aberrant novelty and salience, and enhanced anticipation of threat contribute...

Sensorimotor gating, cannabis use and the risk of psychosis

Schizophrenia Research May 1, 2015 Toby T Winton-Brown, V. Kumari, F. Windler et al.

Sensorimotor gating, measured as the modification of eye blink startle reflexes to loud acoustic stimuli by quieter preceding stimuli, is altered in those with psychosis, their relatives and those at high clinical risk for psychosis. Alterations have also been shown in cannabis users, albeit to a lesser extent, and cannabis is a known risk factor for the onset of psychosis in clinically and...

Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors

Psychiatry Research April 15, 2015 Sania Shakoor, Helena M. S. Zavos, Philip Mcguire et al. 37 citations

Cannabis users are more likely to have psychotic experiences (PEs). The degree to which these associations are driven by genetic or environmental influences in adolescence is unknown. This study estimated the genetic and environmental contributions to the relationship between cannabis use and PEs. Specific PEs were measured in a community-based twin sample (4830 16-year-old pairs) using...

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

Psychological Medicine October 1, 2012 Zerrin Atakan, Sagnik Bhattacharyya, Paul Allen et al. 54 citations

BACKGROUND: Cannabis can induce transient psychotic symptoms, but not all users experience these adverse effects. We compared the neural response to Δ9-tetrahydrocannabinol (THC) in healthy volunteers in whom the drug did or did not induce acute psychotic symptoms. Method In a double-blind, placebo-controlled, pseudorandomized design, 21 healthy men with minimal experience of cannabis were...

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Current Pharmaceutical Design September 12, 2012 Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al. 288 citations

RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...

Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Schizophrenia Bulletin January 26, 2012 Oliver Howes, Paul Shotbolt, Michael Bloomfield et al. 94 citations

Background: The psychosis phenotype appears to exist in the population as a continuum, but it is not clear if subclinical psychotic symptoms and psychotic disorders share the same neurobiology. We investigated whether the dopaminergic dysfunction seen in psychotic disorders is also present in healthy, well-functioning people with hallucinations. Methods: We compared dopamine synthesis capacity...

Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

Archives of General Psychiatry January 2012 Sagnik Bhattacharyya, José Alexandre S. Crippa, Paul Allen et al.

The aberrant processing of salience is thought to be a fundamental factor underlying psychosis. Cannabis can induce acute psychotic symptoms, and its chronic use may increase the risk of schizophrenia. We investigated whether its psychotic effects are mediated through an influence on attentional salience processing. To examine the effects of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol...

Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.

Neuropsychopharmacology June 2011 Toby T Winton-Brown, Paul Allen, Sagnik Bhattacharyya et al.

Although the effects of cannabis on perception are well documented, little is known about their neural basis or how these may contribute to the formation of psychotic symptoms. We used functional magnetic resonance imaging (fMRI) to assess the effects of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) during visual and auditory processing in healthy volunteers. In total, 14 healthy...

Delta-9-Tetrahydrocannabinol Disruption of Time Perception and of Self-Timed Actions

Pharmacopsychiatry July 22, 2010 James Stone, Paul D. Morrison, Judith Nottage et al. 13 citations

We tested the hypothesis that THC disrupts self-timed actions in healthy volunteers, and that this effect is related to self-rated perceptions of time distortion. We found that THC impaired subjective time perception and reduced the rate of button pressing, although the change in the rate of button pressing was more closely related to impaired concentration and intoxication. We conclude that...

DOI: 10.1055/s-0030-1255030 (opens in new tab) Time perception Delta-9-tetrahydrocannabinol Mechanism biology Δ9-tetrahydrocannabinol +2